Safinamide for Multiple System Atrophy (MSA)

Summary

The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner. Study population is patients diagnosed, with possible or probable parkinsonian variant of Multiple System Atrophy who are on a stable treatment of levodopa

Timeline

Start

2019-10-29

Primary completion

2021-01-05

Completion

2021-01-05

Drugs

Indications